

1 **Title: Exploring the effects of BCG vaccination in patients diagnosed with**
2 **tuberculosis: observational study using the Enhanced Tuberculosis**
3 **Surveillance system**

4 Sam Abbott, Hannah Christensen, Maeve K Lalor, Dominik Zenner, Colin Campbell, Mary
5 Ramsay, Ellen Brooks-Pollock

6 **Authors:**

7 Sam Abbott, Bristol Medical School: Population Health Sciences, University of Bristol,
8 Bristol, UK

9 Hannah Christensen, Bristol Medical School: Population Health Sciences, University of
10 Bristol, Bristol, UK

11 Maeve K Lalor, TB Unit, T.A.R.G.E.T, National Infection Service (NIS), Public Health England,
12 London, UK

13 Dominik Zenner, Institute for Global Health, University College London, London, UK

14 Colin Campbell, TB Unit, T.A.R.G.E.T, National Infection Service (NIS), Public Health
15 England, London, UK

16

17 Mary E Ramsay, Immunisation, Hepatitis and Blood safety department, Public Health
18 England, London, UK

1 Ellen Brooks-Pollock, Bristol Medical School: Population Health Sciences, University of
2 Bristol, Bristol, UK

3 **Correspondence to:** Sam Abbott, Bristol Medical School: Population Health Sciences,
4 University of Bristol, Bristol BS8 2BN, UK; sam.abbott@bristol.ac.uk; 01173310185

5 **WORD COUNT: Title** 19 (20), **Abstract** 220 (300), **Paper** 3241 (5000)

1

2 **ABSTRACT**

3 **Background**

4 Bacillus Calmette–Guérin (BCG) is one of the most widely-used vaccines worldwide. BCG
5 primarily reduces the progression from infection to disease, however there is evidence that
6 BCG may provide additional benefits. We aimed to investigate whether there is evidence in
7 routinely-collected surveillance data that BCG vaccination impacts outcomes for
8 tuberculosis (TB) cases in England.

9 **Methods**

10 We obtained all TB notifications for 2009-2015 in England from the Enhanced Tuberculosis
11 surveillance system. We considered five outcomes: All-cause mortality, death due to TB (in
12 those who died), recurrent TB, pulmonary disease, and sputum smear status. We used
13 logistic regression, with complete case analysis, to investigate each outcome with BCG
14 vaccination, years since vaccination and age at vaccination, adjusting for potential
15 confounders. All analyses were repeated using multiply imputed data.

16 **Results**

17 We found evidence of an association between BCG vaccination and reduced all-cause
18 mortality (aOR:0.76 (95%CI 0.64 to 0.89), P:0.001) and weak evidence of an association
19 with reduced recurrent TB (aOR:0.90 (95%CI 0.81 to 1.00), P:0.056). Analyses using
20 multiple imputation suggested that the benefits of vaccination for all-cause mortality were
21 reduced after 10 years.

1 **Conclusions**

2 We found that BCG vaccination was associated with reduced all-cause mortality in people
3 with TB although this benefit was less pronounced more than 10 years after vaccination.

4 There was weak evidence of an association with reduced recurrent TB.

5 **Keywords:** Tuberculosis, BCG, Surveillance, Non-specific, Mortality

6 **Highlights**

- 7 • Found evidence of an association between BCG vaccination and reduced all-cause
8 mortality in TB cases.
- 9 • Weaker evidence of an association between BCG vaccination and reduced repeat TB
10 episodes in TB cases.
- 11 • There was little evidence of an association with other TB outcomes.
- 12 • There was weak evidence of associations between TB outcomes and age at, or years
13 since, vaccination.

1

2 INTRODUCTION

3 Bacillus Calmette–Guérin (BCG) is one of the mostly widely-used vaccines and the only
4 vaccine that protects against tuberculosis (TB) disease. BCG was first used in humans in
5 1921 and was introduced into the WHO Expanded Program on Immunization in 1974.[1]

6 BCG vaccination has been controversial due to its variable efficacy and possibility of
7 causing a false positive result with the standard skin test for TB.[2] However, the lack of a
8 more effective vaccine and the emergence of drug-resistant TB strains means that BCG
9 vaccination remains an important tool for reducing TB incidence and mortality rates.

10 BCG's primary mode of action is to directly prevent the development of active, symptomatic
11 disease. Its efficacy in adults is context specific, with estimates ranging between 0% and
12 78%.[3] It has been shown to highly efficacious in England and there is some evidence that
13 efficacy increases with distance from the equator. Efficacy has been shown to be dependent
14 on previous exposure, with unexposed individuals receiving the greatest benefit.[4] Unlike
15 in adults, BCG has consistently been shown to be highly protective against TB and TB
16 meningitis in children.[5,6] For this reason the majority of countries that use BCG,
17 vaccinate at birth.[7,8] Adult vaccination is no longer common in the UK, where universal
18 BCG vaccination of adolescents was stopped in 2005 in favour of a targeted neonatal
19 programme aimed at high risk children.

20 Vaccination policy has been primarily based on reducing the incidence of TB disease, and
21 mitigating disease severity, with little attention having been given to any additional effects
22 of BCG vaccination on TB outcomes..[9,10] There is some evidence that BCG vaccination
23 induces innate immune responses which may provide non-specific protection,[11] TB

1 patients with BCG scars were found to respond better to treatment with earlier sputum
2 smear conversion,[12] and there is evidence to suggest that BCG vaccination is associated
3 with reduced all-cause neonatal mortality[13,14] and both reduced TB[15] and all-
4 cause[16] mortality in the general population. Given that the immunology behind TB
5 immunity is not fully understood these findings suggest that BCG may play a more
6 important role in improving TB outcomes than previously thought. We aimed to quantify
7 the effects of BCG vaccination on outcomes for individuals with notified TB in England
8 using routinely collected surveillance data to provide evidence for appropriate public
9 health action and provision. Where we found an association, we additionally explored the
10 role of years since vaccination, and age at vaccination.

1

2 **METHOD**

3 **Enhanced Tuberculosis Surveillance (ETS) system**

4 We extracted all notifications from the Enhanced Tuberculosis Surveillance (ETS) system
5 from January 1, 2009 to December 31, 2015. BCG vaccination status and year of vaccination
6 have been collected since 2008. The outcomes we considered were: all-cause mortality,
7 death due to TB (in those who died), recurrent TB, pulmonary disease, and sputum smear
8 status. These outcomes were selected based on: their availability in the ETS; evidence from
9 the literature of prior associations with BCG vaccination; associations with increased case
10 infectiousness; or severe outcomes for patients.

11 All-cause mortality was defined using the overall outcome recorded in ETS, this is based on
12 up to 36 months of follow up starting from date of starting treatment. Follow up ends when
13 a case is recorded as completing treatment, with treatment status evaluated at 12, 24, and
14 36 months from starting treatment. Where the treatment start date was not available the
15 notification date was used if appropriate. The date of death was validated against Office for
16 National Statistics (ONS) data. Those that were lost to follow up, or not evaluated were
17 treated as missing. In cases with a known cause of death, death due to TB was defined as
18 those that died from TB, or where TB had contributed to their death. Cause of death was
19 recorded by case managers. TB cases who had recurrent episodes were identified using
20 probabilistic matching. Positive sputum smear status was given to cases that had a sputum
21 sample shown to contain Acid-Fast Bacilli. A positive sputum smear status indicates that
22 cases are more likely to be infectious. Cases were defined as having pulmonary TB if a
23 positive sputum smear sample was recorded, if a positive culture was grown from a

1 pulmonary laboratory specimen, or if they were clinically assessed as having pulmonary
2 TB.

3 **Exposure variables relating to BCG**

4 We included three exposure variables related to BCG: BCG status (vaccinated, yes/no),
5 years since vaccination and age at vaccination.

6 BCG status was collected and recorded in ETS by case managers. Information on BCG
7 vaccination status may have come from vaccination records, patient recall or the presence
8 of a scar. When cases are uncertain, and there is no evidence of a scar, no BCG status is
9 given. Year of vaccination was collected similarly. Years since BCG vaccination was defined
10 as year of notification minus year of vaccination and categorised into two groups (0 to 10
11 and 11+ years). This was based on: evidence that the average duration of BCG protection is
12 at least 10-15 years;[15] increasing recall bias with time since vaccination, and any
13 association between years since vaccination and TB outcomes may be non-linear. Age at
14 vaccination is defined in the online supplementary information.

15 **Statistical Analysis**

16 R was used for all statistical analysis.[17] The analysis was conducted in two stages. Firstly,
17 we calculated proportions for all demographic and outcome variables, and compared
18 vaccinated and unvaccinated TB cases using the χ^2 test. Secondly, we used logistic
19 regression, with complete case analysis, to estimate the association between exposures and
20 outcome variables, both with and without adjustment for confounders.

1 In the multivariable models, we adjusted for sex,[18–20] age,[21] Index of Multiple
2 Deprivation (2010) categorised into five groups for England (IMD rank),[22,23]
3 ethnicity,[18,24] UK birth status,[25,26] and year of notification. As the relationship
4 between age and outcomes was non-linear, we modelled age using a natural cubic spline
5 with knots at the 25%, 50% and 75% quantiles.

6 We conducted sensitivity analyses to assess the robustness of the results, by dropping each
7 confounding variable in turn and assessing the effect on the adjusted Odds Ratios (aORs) of
8 the exposure variable. We repeated the analysis excluding duplicate recurrent cases, and
9 restricting the study population to those eligible for the BCG schools scheme (defined as UK
10 born cases that were aged 14 or over in 2004) to assess the comparability of the BCG
11 vaccinated and unvaccinated populations. To mitigate the impact of missing data we used
12 multiple imputation, with the MICE package.[27] We imputed 50 data sets (for 20
13 iterations) using all outcome and explanatory variables included in the analysis as
14 predictors along with Public Health England centre. The model results were pooled using
15 the small sample method,[28] and effect sizes compared with those from the main analysis.

16 **RESULTS**

17 **Description of the data**

18 There were 51,645 TB notifications between 2009-2015 in England. Reporting of
19 vaccination status and year of vaccination improved over time: 64.9% (20865/32154) of
20 notifications included vaccination status for 2009 to 2012, increasing to 70%
21 (13647/19491) from 2013 to 2015. The majority of cases that had a known vaccination

1 status were vaccinated (70.6%, 24354/34512), and where age and year of vaccination was
2 known, the majority of cases were vaccinated at birth (60%, 5979/10066).
3 Vaccinated cases were younger than unvaccinated cases on average (median age 34 years
4 (IQR 26 to 45) compared to 38 years (IQR 26 to 62)). A higher proportion of non-UK born
5 cases were BCG vaccinated, (72.7%, 18297/25171) compared to UK born cases (65.2%,
6 5787/8871, P: < 0.001) and, of those vaccinated, a higher proportion of non-UK born cases
7 were vaccinated at birth compared to UK born cases (68%, 4691/6896 vs. 40.5%,
8 1253/3096 respectively, P: < 0.001). See table 1 for the breakdown of outcome variables
9 table 2 for the breakdown of confounding variables.

1

2 **Table 1:** Outcomes for individuals in England notified with tuberculosis between 2009-2015,
 3 stratified by BCG vaccination status.

Outcome	Total	Vaccinated	Unvaccinated	Unknown vaccine status
Total, all cases	51645	24354 {47}	10158 {20}	17133 {33}
All-cause mortality	45588 (88)	21685 (89)	9061 (89)	14842 (87)
No	43024 [94]	21291 [98]	8495 [94]	13238 [89]
Yes	2564 [6]	394 [2]	566 [6]	1604 [11]
Death due to TB (in those who died*)	1373 (3)	276 (1)	320 (3)	777 (5)
No	572 [42]	129 [47]	146 [46]	297 [38]
Yes	801 [58]	147 [53]	174 [54]	480 [62]
Recurrent TB	48497 (94)	23963 (98)	9991 (98)	14543 (85)
No	44869 [93]	22592 [94]	9256 [93]	13021 [90]
Yes	3628 [7]	1371 [6]	735 [7]	1522 [10]
Pulmonary TB	51432 (100)	24289 (100)	10121 (100)	17022 (99)
Extra-pulmonary (EP) only	24280 [47]	12085 [50]	4573 [45]	7622 [45]

Pulmonary, with or without EP	27152 [53]	12204 [50]	5548 [55]	9400 [55]
Sputum smear status	19551 (38)	9768 (40)	3910 (38)	5873 (34)
Negative	11060 [57]	5694 [58]	2231 [57]	3135 [53]
Positive	8491 [43]	4074 [42]	1679 [43]	2738 [47]

{% all cases}{% complete within vaccine status)[% *complete within category*],

* Death due to TB in those who died and where cause of death was known

1 **Table 2:** Confounders for individuals in England notified with tuberculosis between 2009-
 2 2015, stratified by BCG vaccination status.

Confounder	Total	Vaccinated	Unvaccinated	Unknown vaccine status
Total, all cases	51645	24354 {47}	10158 {20}	17133 {33}
Age	51645 (100)	24354 (100)	10158 (100)	17133 (100)
Mean [SD]	40 [19]	36 [16]	44 [22]	45 [20]
Median [25%, 75%]	36 [27, 52]	34 [26, 45]	38 [26, 62]	41 [29, 59]
Sex	51535 (100)	24320 (100)	10136 (100)	17079 (100)
Female	22066 [43]	10791 [44]	4312 [43]	6963 [41]
Male	29469 [57]	13529 [56]	5824 [57]	10116 [59]
IMD rank (with 1 as most deprived and 5 as least deprived)*	43525 (84)	21240 (87)	8866 (87)	13419 (78)
1	16800 [39]	7779 [37]	3665 [41]	5356 [40]
2	13057 [30]	6836 [32]	2564 [29]	3657 [27]
3	6838 [16]	3459 [16]	1259 [14]	2120 [16]
4	4045 [9]	1893 [9]	836 [9]	1316 [10]
5	2785 [6]	1273 [6]	542 [6]	970 [7]
UK birth status	49820 (96)	24084 (99)	9958 (98)	15778 (92)
Non-UK Born	36988 [74]	18297 [76]	6874 [69]	11817 [75]

UK Born	12832 [26]	5787 [24]	3084 [31]	3961 [25]
Ethnic group	50416 (98)	24074 (99)	10024 (99)	16318 (95)
White	10194 [20]	3560 [15]	2695 [27]	3939 [24]
Black-Caribbean	1112 [2]	559 [2]	242 [2]	311 [2]
Black-African	8942 [18]	4620 [19]	1602 [16]	2720 [17]
Black-Other	462 [1]	261 [1]	80 [1]	121 [1]
Indian	12994 [26]	7176 [30]	2061 [21]	3757 [23]
Pakistani	8237 [16]	3512 [15]	1720 [17]	3005 [18]
Bangladeshi	2025 [4]	918 [4]	480 [5]	627 [4]
Chinese	601 [1]	289 [1]	101 [1]	211 [1]
Mixed / Other	5849 [12]	3179 [13]	1043 [10]	1627 [10]
Calendar year	51645 (100)	24354 (100)	10158 (100)	17133 (100)

{% all cases}(% complete within vaccine status)[% complete within category],

* Index of Multiple Deprivation (2010) categorised into five groups for England

1 All-cause mortality

2 In the univariable analysis the odds of death from any cause were lower for BCG vaccinated
3 TB cases compared to unvaccinated cases, with an OR of 0.28 (95% CI 0.24 to 0.32, P:
4 <0.001) (table 3, see supplementary table S1 for the full table); an association remained
5 after adjusting for confounders, but was attenuated with an aOR of 0.76 (95% CI 0.64 to
6 0.89, P: 0.001). We estimate that if all unvaccinated cases had been vaccinated there would
7 have been on average 19 (95% CI 9 to 29) fewer deaths per year during the study period

1 (out of 81 deaths per year on average in unvaccinated cases). Whilst there was evidence in
2 univariable analyses to suggest all-cause mortality was higher in persons vaccinated more
3 than 10 years prior to notification of TB and that all-cause mortality increased with
4 increasing age group, these disappeared after adjusting for potential confounders (table 4,
5 supplementary table S2).

6 Similar results to the multivariable analysis were found using multiply imputed data for the
7 association between vaccination status and all-cause mortality (aOR: 0.76 (95% CI 0.61 to
8 0.94), P: 0.013), but not for time since vaccination with a greatly increased risk of all-cause
9 mortality estimated for those vaccinated more than 10 years before case notification,
10 compared to those vaccinated more recently (aOR: 12.19 (95% CI 3.48 to 42.64), (see
11 online supplementary table S3, supplementary table S4)). For age at vaccination results for
12 the multivariable analysis using multiply imputed data were comparable to those found
13 using complete case analysis, except that there was some evidence that vaccination in
14 adolescence, compared to under 1, was associated with increased, rather than decreased,
15 all-cause mortality (aOR: 1.57 (95% CI 1.13 to 2.19), supplementary table S5).

16 **Deaths due to TB (in those who died)**

17 There was little evidence of any association between BCG vaccination and deaths due to TB
18 (in those who died and where cause of death was known) in the univariable analysis (table
19 3). The adjusted point estimate indicated an association between BCG vaccination and
20 reduced deaths due to TB (in those who died) although the confidence intervals remained
21 wide with a similar result found using multiply imputed data (see online supplementary
22 table S3). There were insufficient data to robustly estimate an association between deaths

1 due to TB (in those who died) and years since vaccination or age at vaccination (table 4,
2 supplementary table S2).

3 **Recurrent TB**

4 In both the univariable and multivariable analysis there was some evidence that BCG
5 vaccination was associated with reduced recurrent TB, although the strength of the
6 evidence was weakened after adjusting for confounders (table 3). In the adjusted analysis,
7 the odds of recurrent TB were lower for BCG vaccinated cases compared to unvaccinated
8 cases, with an aOR of 0.90 (95% CI 0.81 to 1.00, P: 0.056). The strength of the evidence for
9 this association was comparable in the analysis using multiply imputed data (see online
10 supplementary table S3). There was little evidence in the adjusted analysis of any
11 association between recurrent TB and years since vaccination (table 4) or age at
12 vaccination (supplementary table S2).

13 **Other Outcomes**

14 After adjusting for confounders there was little evidence for any association between BCG
15 vaccination and pulmonary disease or positive sputum smear status (table 3); similar
16 results were found using multiply imputed data (see online supplementary table S3).

Table 3: Summary of associations between BCG vaccination and all outcomes. Cases represents all notifications with complete data and a given BCG status, regardless of outcome. Cases with outcome is similarly defined but includes only cases with the specified outcome.

Outcome	BCG vaccinated	Univariable				Multivariable			
		Cases*	Cases with outcome (%)	OR (95% CI)	P-value	Cases †	Cases with outcome (%)	aOR (95% CI)	P-value
All-cause mortality	No	9061	566 (6)	1	<0.001	7620	473 (6)	1	0.001
	Yes	21685	394 (2)	0.28 (0.24 to 0.32)		1837	334 (2)	0.76 (0.64 to 0.89)	
Death due to TB (in	No	320	174 (54)	1	0.786	270	143 (53)	1	0.177
	Yes	276	147 (53)	0.96 (0.69 to 1.32)		236	126 (53)	0.76 (0.51 to 1.13)	

those who

died‡)

Recurrent	No	9991	735 (7)	1	<0.001	8502	615 (7)	1	0.056
TB	Yes	23963	1371 (6)	0.76 (0.70 to 0.84)		2058	1177 (6)	0.90 (0.81 to 1.00)	
						4			
Pulmonary	No	10121	5548 (55)	1	<0.001	8595	4685 (55)	1	0.769
TB	Yes	24289	12204	0.83 (0.79 to 0.87)		2078	10342 (50)	0.99 (0.94 to 1.05)	
			(50)			4			
Sputum	No	3910	1679 (43)	1	0.187	3367	1435 (43)	1	0.730
smear status	Yes	9768	4074 (42)	0.95 (0.88 to 1.02)		8351	3447 (41)	1.02 (0.93 to 1.11)	

- positive

OR (95% CI): unadjusted odds ratio with 95% confidence intervals,

aOR (95% CI): adjusted odds ratios with 95% confidence intervals,

* Univariable sample size for outcomes ordered as in table (% of all cases) = 30746 (60%), 596 (23%), 33954 (66%), 34410 (67%), 13678 (26%),

† Multivariable sample size with outcomes ordered as in table (% of all cases) = 25993 (50%), 506 (20%), 29086 (56%), 29379 (57%), 11718 (23%),

‡ Death due to TB in those who died and where cause of death was known

Table 4: Summary of associations between years since vaccination and all outcomes in individuals who were vaccinated. The baseline exposure is vaccination ≤ 10 years before diagnosis compared to vaccination 11 + years before diagnosis. Deaths due to TB (in those who died) had insufficient data for effect sizes to be estimated in both the univariable and multivariable analysis. Cases represents all notifications with complete data and a given BCG status, regardless of outcome. Cases with outcome is similarly defined but includes only cases with the specified outcome.

Outcome	Years since BCG	Univariable				Multivariable			
		Cases*	Cases with outcome (%)	OR (95% CI)	P-value	Cases†	Cases with outcome (%)	aOR (95% CI)	P-value
All-cause mortality	≤ 10	718	5 (1)	1	0.004	554	4 (1)	1	0.897
	11+	8106	166 (2)	2.98 (1.22 to 7.28)		7171	148 (2)	0.91 (0.24 to 3.54)	
Death due to TB (in those who died‡)	≤ 10	2	2 (100)	1	-	2	2 (100)	1	-
	11+	108	59 (55)	<i>Insufficient data</i>		98	53 (54)	<i>Insufficient data</i>	

Recurrent	≤ 10	780	22 (3)	1	0.005	613	14 (2)	1	0.515
TB	11+	9172	451 (5)	1.78 (1.15 to 2.75)		8194	406 (5)	1.24 (0.63 to 2.44)	
Pulmonary	≤ 10	770	480 (62)	1	<0.001	601	382 (64)	1	0.309
TB	11+	9248	4757 (51)	0.64 (0.55 to 0.74)		8254	4232 (51)	0.87 (0.67 to 1.14)	
Sputum	≤ 10	157	81 (52)	1	0.941	122	61 (50)	1	0.920
smear status	11+	3064	1590 (52)	1.01 (0.73 to 1.40)		2734	1405 (51)	1.02 (0.68 to 1.54)	
- positive									

OR (95% CI): unadjusted odds ratio with 95% confidence intervals, aOR (95% CI): adjusted odds ratios with 95% confidence intervals,

* Univariable sample size for outcomes ordered as in table (% of vaccinated cases) = 8824 (36%), 110 (28%), 9952 (41%), 10018 (41%), 3221 (13%),

† Multivariable sample size with outcomes ordered as in table (% of vaccinated cases) = 7725 (32%), 100 (25%), 8807 (36%), 8855 (36%), 2856 (12%),

‡ Death due to TB in those who died and where cause of death was known

1 **Sensitivity analysis**

2 Dropping duplicate recurrent TB notifications increased the magnitude, and precision, of
3 the effect sizes for recurrent TB, all-cause mortality, and deaths due to TB (in those who
4 died) (see online supplementary table S6). Restricting the analysis to only cases that were
5 eligible for the BCG schools scheme reduced the sample size of the analysis (from an initial
6 study size of 51645, of which 12832 were UK born, to 9943 cases that would have been
7 eligible for the BCG schools scheme). With this reduced sample size, there was strong
8 evidence in adjusted analyses of an association between BCG vaccination and reduced
9 recurrent TB, and evidence of an association with decreased all-cause mortality (see online
10 supplementary table S6).

1

2 **DISCUSSION**

3 Using TB surveillance data collected in England we found that BCG vaccination, prior to the
4 development of active TB, was associated with reduced all-cause mortality and fewer
5 recurrent TB cases, although the evidence for this association was weaker. There was some
6 suggestion that the association with all-cause mortality was due to reduced deaths due to
7 TB (in those who died), though the study was underpowered to definitively assess this. We
8 did not find evidence of an association between BCG status and positive smear status or
9 pulmonary TB. Analysis with multiply imputed data indicated that notification 10+ years
10 after vaccination was associated with increased all-cause mortality. In separate analyses,
11 there was some evidence that vaccination at birth, compared to at any other age, was
12 associated with reduced all-cause mortality, and increased deaths due to TB (in those who
13 died).

14 This study used a large detailed dataset, with coverage across demographic groups, and
15 standardized data collection from notifications and laboratories. The use of routine
16 surveillance data means that this study would be readily repeatable with new data. The
17 surveillance data contained multiple known risk factors, this allowed us to adjust for these
18 confounders in the multivariable analysis, which attenuated the evidence for an association
19 with BCG vaccination for all outcomes. However, there are important limitations to
20 consider. The study was conducted within a population of active TB cases, therefore the
21 association with all-cause mortality cannot be extrapolated to the general population.
22 Additionally, vaccinated and unvaccinated populations may not be directly comparable
23 because vaccination has been targeted at high-risk neonates in the UK since 2005. We

1 mitigated this potential source for bias by conducting a sensitivity analysis including only
2 those eligible for the universal school age scheme, and whilst the strength of associations
3 were attenuated there remained some evidence of improved outcomes. Sensitivity analysis
4 excluding recurrent cases indicated their inclusion may have biased our results towards
5 the null.

6 Variable data completeness changed with time, with both BCG vaccination status and year
7 of vaccination having a high percentage of missing data, which may not be missing
8 completely at random. We therefore checked the robustness of our results with multiple
9 imputation including regional variability, however an unknown missing not at random
10 mechanism, or unmeasured confounding may still have introduced bias. We found a greatly
11 increased risk of all-cause mortality for those vaccinated more than 10 years ago in the
12 analysis with multiply imputed data, compared to the complete case analysis. This is likely
13 to be driven by a missing not at random mechanism for years since vaccination, with older
14 cases being both more likely to have been vaccinated more than 10 years previously and to
15 also have an unknown year of vaccination. The high percentage of missing data also means
16 that we were likely to be underpowered to detect an effect of BCG vaccination on sputum
17 smear status and deaths due to TB (in those who died), with years since vaccination, and
18 age at vaccination likely to be underpowered for all outcomes. We were not able to adjust
19 for either tuberculin skin test (TST) stringency, or the latitude effect, although we were
20 able to adjust for UK birth status.[29] However, the bias induced by these confounders is
21 likely to be towards the null, meaning that our effect estimates are likely to be conservative.
22 We could also not adjust for the BCG strain each individual may have received, the BCG
23 strain used may vary both temporally and geographically. Finally, BCG vaccination status,

1 and year of vaccination, may be subject to misclassification due to recall bias; validation
2 studies of the recording of BCG status in the ETS would be required to assess this.

3 Little work has been done to assess the overall effect of BCG on outcomes for active TB
4 cases although the possible non-specific effects of BCG are an area of active
5 research.[14,30,31] Whilst multiple studies have investigated BCG's association with all-
6 cause mortality, it has been difficult to assess whether the association continues beyond
7 the first year of life.[31] The effect size of the association we identified between BCG and
8 all-cause mortality in active TB cases was comparable to that found in a Danish case-cohort
9 study in the general population (aHR: 0.58 (95% CI 0.39 to 0.85)).[16] A recent systematic
10 review also found that BCG vaccination was associated with reduced all-cause mortality in
11 neonates, with an average relative risk of 0.70 (95% CI 0.49 to 1.01) from five clinical trials
12 and 0.47 (95% CI 0.32 to 0.69) from nine observational studies at high risk of bias.[14] We
13 found some weak evidence that BCG vaccination was associated with reduced deaths due
14 to TB (in those who died), although our point estimate had large confidence intervals.

15 Several meta-analyses have found evidence supporting this association,[6,15] with one
16 meta-analysis estimating a 71% (RR: 0.29 95% CI 0.16 to 0.53) reduction in deaths due to
17 TB in individuals vaccinated with BCG.[6] The meta-analysis performed by Abubakar et
18 al. also found consistent evidence for this association, with a Rate Ratio of 0.22 (95% CI
19 0.15 to 0.33).[15] In contrast to our study, both of these meta-analyses estimated the
20 protection from TB mortality in BCG vaccinated individuals rather than in BCG vaccinated
21 cases who had died from any cause. Additionally, neither study explored the association
22 between BCG vaccination and all-cause mortality or recurrent TB. This study could not
23 determine the possible causal pathway for the association between BCG vaccination all-

1 cause mortality, and recurrent TB. These are important to establish in order to understand
2 the effect of BCG vaccination on TB outcomes.

3 We found that BCG vaccination was associated with reduced all-cause mortality, with some
4 weaker evidence of an association with reduced recurrent TB. A plausible mechanism for
5 this association is that BCG vaccination improves treatment outcomes,[12] which then
6 results in decreased mortality, and reduced recurrent TB. However, these effects may also
7 be independent and for all-cause mortality may not be directly related to active TB. In this
8 case, a possible mechanism for the association between BCG vaccination and all-cause
9 mortality is that BCG vaccination modulates the innate immune response, resulting in non-
10 specific protection.[11] For low incidence countries, where the reduction in TB cases has
11 been used as evidence to scale back vaccination programs,[7] these results suggest that
12 BCG vaccination may be more beneficial than previously thought. In countries that target
13 vaccination at those considered to be at high risk of TB the results from this study could be
14 used to help drive uptake by providing additional incentives for vaccination. The evidence
15 we have presented should be considered in future cost-effectiveness studies of BCG
16 vaccination programs.

17 Further work is required to determine whether years since vaccination and age at
18 vaccination are associated with TB outcomes as this study was limited by low sample size,
19 missing data for year of vaccination, and the relative rarity of some TB outcomes. However,
20 due to the continuous collection of the surveillance data used in this analysis, this study
21 could be repeated once additional data have been collected. If this study were to be
22 repeated with a larger sample size particular attention should be given to the functional

1 form of any decay in protection from negative TB outcomes. Additionally, a larger sample
2 size would allow investigation of the associations identified between TB outcomes and BCG
3 vaccination stratified by pulmonary, extrapulmonary, and disseminated TB disease.
4 Between country variations in the strength of associations could also be explored as a
5 proxy to BCG strain using sub-group analysis. The results from this study require validation
6 in independent datasets and the analysis should be reproducible in other low incidence
7 countries that have similarly developed surveillance systems. If validated in low incidence
8 countries, similar studies in medium to high incidence countries should be conducted
9 because any effect would have a greater impact in these settings.

10 **Acknowledgements**

11 The authors thank the TB section at Public Health England (PHE) for maintaining the
12 Enhanced Tuberculosis Surveillance (ETS) system; all the healthcare workers involved in
13 data collection for the ETS.

14 **Contributors**

15 SA, HC, and EBP conceived and designed the work. SA undertook the analysis with advice
16 from all other authors. All authors contributed to the interpretation of the data. SA wrote
17 the first draft of the paper and all authors contributed to subsequent drafts. All authors
18 approve the work for publication and agree to be accountable for the work.

19 **Funding**

20 SEA, HC, and EBP are funded by the National Institute for Health Research Health
21 Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at University of

1 Bristol in partnership with Public Health England (PHE). The views expressed are those of
2 the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or
3 Public Health England.

4 **Conflicts of interest**

5 HC reports receiving honoraria from Sanofi Pasteur, and consultancy fees from
6 AstraZeneca, GSK and IMS Health, all paid to her employer.

7 **Accessibility of data and programming code**

8 The code for the analysis contained in this paper can be found at:

9 doi.org/10.5281/zenodo.1213799

10

1

2 **REFERENCES**

3 [1] The World Health Organization. BCG Vaccine. Weekly Epidemiological Record
4 2004;79:27–48.

5 [2] Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: A
6 database of global BCG vaccination policies and practices. PLoS Medicine 2011;8.
7 doi:[10.1371/journal.pmed.1001012](https://doi.org/10.1371/journal.pmed.1001012).

8 [3] Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PEM, et al. Protection by BCG
9 Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials.
10 Clinical Infectious Diseases 2014;58:470–80. doi:[10.1093/cid/cit790](https://doi.org/10.1093/cid/cit790).

11 [4] Barreto ML, Pilger D, Pereira SM, Genser B, Cruz AA, Cunha SS, et al. Causes of variation
12 in BCG vaccine efficacy: Examining evidence from the BCG REVAC cluster randomized trial
13 to explore the masking and the blocking hypotheses. Vaccine 2014;32:3759–64.
14 doi:[10.1016/j.vaccine.2014.05.042](https://doi.org/10.1016/j.vaccine.2014.05.042).

15 [5] Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous
16 meningitis and miliary tuberculosis: a meta-analysis. International Journal of Epidemiology
17 1993;22:1154–8.

18 [6] Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of
19 BCG Vaccine in the Prevention of Tuberculosis. JAMA 1994;271:698.
20 doi:[10.1001/jama.1994.03510330076038](https://doi.org/10.1001/jama.1994.03510330076038).

- 1 [7] Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a
2 database of global BCG vaccination policies and practices. PLoS Medicine 2011;8:e1001012.
3 doi:[10.1371/journal.pmed.1001012](https://doi.org/10.1371/journal.pmed.1001012).
- 4 [8] Organization WH, Appia A, Geneva C. BCG vaccine : WHO position paper , February
5 2018 – Recommendations. Vaccine 2018;36:3408–10. doi:[10.1016/j.vaccine.2018.03.009](https://doi.org/10.1016/j.vaccine.2018.03.009).
- 6 [9] Fine P. Stopping routine vaccination for tuberculosis in schools. BMJ (Clinical Research
7 Ed) 2005;331:647–8. doi:[10.1136/bmj.331.7518.647](https://doi.org/10.1136/bmj.331.7518.647).
- 8 [10] Teo SSS. Does BCG have a role in tuberculosis control and prevention in the United
9 Kingdom? Archives of Disease in Childhood 2006;91:529–31.
10 doi:[10.1136/adc.2005.085043](https://doi.org/10.1136/adc.2005.085043).
- 11 [11] Kleinnijenhuis J, Quintin J, Preijers F, Joosten LAB, Ifrim DC, Saeed S, et al. Bacille
12 Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via
13 epigenetic reprogramming of monocytes. Proceedings of the National Academy of Sciences
14 of the United States of America 2012;109:17537–42. doi:[10.1073/pnas.1202870109](https://doi.org/10.1073/pnas.1202870109).
- 15 [12] Jeremiah K, Praygod G, Faurholt-Jepsen D, Range N, Andersen AB, Grewal HMS, et al.
16 BCG vaccination status may predict sputum conversion in patients with pulmonary
17 tuberculosis: a new consideration for an old vaccine? Thorax 2010;65:1072–6.
18 doi:[10.1136/thx.2010.134767](https://doi.org/10.1136/thx.2010.134767).
- 19 [13] Garly ML, Martins CL, Balé C, Baldé MA, Hedegaard KL, Gustafson P, et al. BCG scar and
20 positive tuberculin reaction associated with reduced child mortality in West Africa: A non-

1 specific beneficial effect of BCG? *Vaccine* 2003;21:2782–90. doi:[10.1016/S0264-](https://doi.org/10.1016/S0264-410X(03)00181-6)
2 [410X\(03\)00181-6](https://doi.org/10.1016/S0264-410X(03)00181-6).

3 [14] Higgins JPT, Soares-weiser K, López-lópez JA, Kakourou A, Chaplin K, Christensen H, et
4 al. Association of BCG , DTP , and measles containing vaccines with childhood mortality :
5 systematic review n.d. doi:[10.1136/bmj.i5170](https://doi.org/10.1136/bmj.i5170).

6 [15] Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne J a C, et al. Systematic
7 review and meta-analysis of the current evidence on the duration of protection by bacillus
8 Calmette-Guérin vaccination against tuberculosis. *Health Technology Assessment*
9 2013;17:1–372, v–vi. doi:[10.3310/hta17370](https://doi.org/10.3310/hta17370).

10 [16] Rieckmann A, Villumsen M, Sørup S, Haugaard LK, Ravn H, Roth A, et al. Vaccinations
11 against smallpox and tuberculosis are associated with better long-term survival: a Danish
12 case-cohort study 1971–2010. *International Journal of Epidemiology* 2016;94:dyw120.
13 doi:[10.1093/ije/dyw120](https://doi.org/10.1093/ije/dyw120).

14 [17] R Core Team. *R: A Language and Environment for Statistical Computing* 2016.

15 [18] Parslow R, El-Shimy NA, Cundall DB, McKinney PA. Tuberculosis, deprivation, and
16 ethnicity in Leeds, UK, 1982-1997. *Archives of Disease in Childhood* 2001;84:109–13.
17 doi:[10.1136/adc.84.2.109](https://doi.org/10.1136/adc.84.2.109).

18 [19] Roth A, Sodemann M, Jensen H, Poulsen A, Gustafson P, Weise C, et al. Tuberculin
19 reaction, BCG scar, and lower female mortality. *Epidemiology (Cambridge, Mass)*
20 2006;17:562–8. doi:[10.1097/01.ede.0000231546.14749.ab](https://doi.org/10.1097/01.ede.0000231546.14749.ab).

- 1 [20] Aaby P, Nielsen J, Benn CS, Trape JF. Sex-differential and non-specific effects of routine
2 vaccinations in a rural area with low vaccination coverage: An observational study from
3 Senegal. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2014;109:77–
4 84. doi:[10.1093/trstmh/tru186](https://doi.org/10.1093/trstmh/tru186).
- 5 [21] Teale C, Goldman JM, Pearson SB. The association of age with the presentation and
6 outcome of tuberculosis: a five-year survey. *Age and Ageing* 1993;22:289–93.
- 7 [22] Department of Communities and Local Government. The English Indices of
8 Deprivation 2010. 2011.
9 doi:[http://dx.doi.org/http://www.communities.gov.uk/publications/corporate/statistics/
10 indices2010technicalreport](http://dx.doi.org/http://www.communities.gov.uk/publications/corporate/statistics/indices2010technicalreport).
- 11 [23] Bhatti N, Law MR, Morris JK, Halliday R, Moore-Gillon J. Increasing incidence of
12 tuberculosis in England and Wales: a study of the likely causes. *BMJ (Clinical Research Ed)*
13 1995;310:967–9. doi:[10.1136/bmj.310.6985.967](https://doi.org/10.1136/bmj.310.6985.967).
- 14 [24] Abubakar I, Laundry MT, French CE, Shingadia D. Epidemiology and treatment outcome
15 of childhood tuberculosis in England and Wales: 1999-2006. *Archives of Disease in
16 Childhood* 2008;93:1017–21. doi:[10.1136/adc.2008.139543](https://doi.org/10.1136/adc.2008.139543).
- 17 [25] French CE, Antoine D, Gelb D, Jones JA, Gilbert RL, Watson JM. Tuberculosis in non-UK-
18 born persons, England and Wales, 2001-2003. *International Journal of Tuberculosis and
19 Lung Disease* 2007;11:577–84.
- 20 [26] Djuretic T, Herbert J, Drobniowski F, Yates M, Smith EG, Magee JG, et al. Antibiotic
21 resistant tuberculosis in the United Kingdom : 2002:477–82.

- 1 [27] Van Buuren S, Groothuis-Oudshoorn K. Multivariate Imputation by Chained Equations.
2 Journal of Statistical Software 2011;45:1–67. doi:[10.1177/0962280206074463](https://doi.org/10.1177/0962280206074463).
- 3 [28] Barnard J, Rubin DB. Small-sample degrees of freedom with multiple imputation.
4 Biometrika 1999;86:948–55. doi:[10.1093/biomet/86.4.948](https://doi.org/10.1093/biomet/86.4.948).
- 5 [29] Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG
6 vaccination against Mycobacterium tuberculosis infection in children: systematic review
7 and meta-analysis. BMJ (Clinical Research Ed) 2014;349:g4643. doi:[10.1136/bmj.g4643](https://doi.org/10.1136/bmj.g4643).
- 8 [30] Kandasamy R, Voysey M, McQuaid F, Nie K de, Ryan R, Orr O, et al. Non-specific
9 immunological effects of selected routine childhood immunisations: systematic review. Bmj
10 2016;i5225. doi:[10.1136/bmj.i5225](https://doi.org/10.1136/bmj.i5225).
- 11 [31] Pollard AJ, Finn A, Curtis N. Non-specific effects of vaccines: plausible and potentially
12 important, but implications uncertain. Archives of Disease in Childhood 2017:archdischild-
13 2015-310282. doi:[10.1136/archdischild-2015-310282](https://doi.org/10.1136/archdischild-2015-310282).

